Keyphrases
Adverse Effects
23%
Aldosterone
33%
Aldosterone Synthase
18%
Aldosterone Synthesis
23%
Androgen Deprivation Therapy
35%
Atorvastatin
39%
Bone Tumor
16%
Breast Cancer
16%
Cancer-specific
16%
Cardiovascular Disease
16%
Cholesterol Levels
16%
Common pitfalls
16%
CYP11B2
22%
Disease-specific Mortality
22%
Endopelvic Fascia
16%
Enhancement Effect
16%
Enzalutamide Resistance
16%
Erectile Dysfunction Treatment
16%
Fadrozole
16%
Finnish Men
16%
High Risk
21%
Large Intestine
20%
Lipid Metabolism
19%
Lipids
19%
Meta-analysis
16%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
18%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
21%
MiR-26a
16%
National Cohort Study
16%
Non-associated
16%
Pharmacoepidemiology
16%
Phase III Clinical Trial
16%
Polygenic Risk Score
16%
Postoperative Incontinence
16%
Prostate Cancer
93%
Prostate Cancer Progression
33%
Prostate Cancer Risk
29%
Radical Prostatectomy
39%
Randomized Clinical Trial
18%
Randomized Double-blind
16%
Rat Colon
16%
Sexual Behavior
21%
Statin Use
33%
Statins
54%
Systematic Meta-analysis
16%
Targeting Mechanism
16%
Testing Effect
16%
Transdermal Estradiol
16%
Tumor Immune Environment
16%
Tumor Targeting
16%
Pharmacology, Toxicology and Pharmaceutical Science
Aldosterone
16%
Aldosterone Synthase
16%
Androgen
35%
Androgen Receptor
5%
Antidiabetic Agent
5%
Atorvastatin
41%
Biological Marker
23%
Bone Cancer
16%
Bone Tumor
16%
Breast Cancer
16%
Cancer Growth
16%
Cancer Incidence
16%
Cancer Mortality
17%
Cardiovascular Disease
16%
Castration Resistant Prostate Cancer
18%
Clinical Study
16%
Cohort Study
19%
Dextran Sulfate
9%
Diethylstilbestrol
16%
Diseases
16%
Enteritis
7%
Enzalutamide
16%
Erectile Dysfunction
16%
Fadrozole
16%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
36%
Hypocholesterolemic Agent
9%
Lactone
5%
Lipidome
10%
Malignant Neoplasm
7%
Neoplasm
8%
Overall Survival
11%
Placebo
20%
Prostate Cancer
100%
Prostate Specific Antigen
11%
Replacement Therapy
16%
Statin (Protein)
49%
Thymidine Kinase 1
16%
Transdermal
16%
Medicine and Dentistry
Adverse Effect
16%
Aldosterone
33%
Aldosterone Synthase
23%
Androgen Deprivation Therapy
16%
Androgen Receptor
6%
Atorvastatin
16%
Cancer Growth
33%
Clinical Study
19%
Colon
19%
Dextran Sulfate
9%
Enteritis
7%
Enuresis
7%
Fadrozole
16%
Fascia
16%
Hazard Ratio
5%
Immunity
16%
Incontinence
16%
Large Intestine
19%
Lipid Metabolism
19%
Meta-Analysis
16%
Meta-Regression
6%
Neoplasm
19%
Overall Survival
11%
Placebo
9%
Prostate Cancer
74%
Prostate Specific Antigen
5%
Prostatectomy
16%
Randomized Clinical Trial
18%
Single Nucleotide Polymorphism
6%
Statin
11%
Surgical Technique
7%
Systematic Review
16%
Thymidine Kinase 1
16%
Urinary System
7%
Urine Incontinence
7%
Western Blot
6%
